Phillip Pang - Jan 24, 2023 Form 4 Insider Report for Vir Biotechnology, Inc. (VIR)

Role
Chief Medical Officer
Signature
/s/ Howard Horn, Attorney-in-Fact
Stock symbol
VIR
Transactions as of
Jan 24, 2023
Transactions value $
-$836,269
Form type
4
Date filed
1/25/2023, 07:01 PM
Previous filing
Jul 21, 2022
Next filing
Feb 21, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VIR Common Stock Award $40K +25.4K +17.64% $1.58* 169K Jan 24, 2023 Direct
transaction VIR Common Stock Award $23.8K +4.59K +2.71% $5.18 174K Jan 24, 2023 Direct
transaction VIR Common Stock Sale -$900K -30K -17.24% $30.00* 144K Jan 24, 2023 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VIR Stock Option (Right to Buy) Options Exercise $0 -25.4K -65.17% $0.00 13.6K Jan 24, 2023 Common Stock 25.4K $1.58 Direct F3
transaction VIR Stock Option (Right to Buy) Options Exercise $0 -4.59K -10.9% $0.00 37.5K Jan 24, 2023 Common Stock 4.59K $5.18 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 28, 2022.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.04, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
F3 1/4 of the shares subject to the stock option vested and became exercisable on July 19, 2019, and the remaining shares vest in 36 equal monthly installments thereafter.
F4 1/4 of the shares subject to the stock option vested and became exercisable on March 11, 2020, and the remaining shares vest in 36 equal monthly installments thereafter.